Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"

Outcome
Finished, no results posted
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
1 October 2019
Ended
1 October 2022
Enrollment
1,350 participants
Sites
1
Primary outcomes
Full genomic sequence analysis carried out by Whole Genome Sequencing (WGS)
Sponsor type
Academic / other
Results posted
No
Last update
18 October 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The GENOME FIRST APPROACH project will enroll patients (n = 450) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and the healthy parents of those affected for trio analysis (N in total 1350).

Detailed description public domain (ClinicalTrials.gov)

In the GENOME FIRST APPROACH (monocentric, prospective, open-label diagnostic) project, patients with molecularly undiagnosed diseases will diagnostically be analyzed by Whole Genome Sequencing (WGS)-trio analysis. The following questions will be leading the project: Primary: • Efficacy of WGS trio analysis in different clinical indications Secondary: * Systematically benchmark WGS analysis to detect genetic variations compared to WES and single nucleotide polymorphism (SNP) array analysis, * Expand the analysis from coding single-nucleotide variants (SNVs) to regulatory mutations, structural variants (SVs), and low complexity regions, * Validate the efficacy of clinical genome trio sequencing in a routine diagnostic setting, * Analyse whether 42x coverage has the potential to discover mosaicism as disease causing mechanism, * Further develop algorithms for integrative analyses of Trio-WGS data with Ribonucleic acid- sequencing (RNA-seq), * Identify de novo alterations and novel disease mechanisms, * Gain fundamental new insights into disease mechanisms and cellular biology, * Combine WGS with further Omics methods to improve genetic diagnostics of future rare disease patients, and * Explore overall financial costs and time to report conclusive data to the patients of the Trio-WGS approach compared to traditional multistep diagnostic approaches using single-gene, panel, whole-exome sequencing (WES) and chromosomal microarray (CMA) (SNP array, array-based comparative genomic hybridization (arrayCGH)) analysis. In addition, healthy parents of the subjects will be included in the project to perform parent-child (trio) analyzes.